Stay updated with breaking news from Philogen Group Description. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and IV
Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology The collaboration has focused on the... | March 28, 2023
PHILOGEN S.p.A. BOARD OF DIRECTORS APPROVES HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2022 (Courtesy English Translation) Revenues from contracts...
Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy treatment of Stage IIIB/C melanoma, in line with expectations.Fibromun further
Investegate announcements from Philogen, Philogen Provides Corporate Update